Ionis Pharmaceuticals (NASDAQ:IONS – Free Report) had its price target reduced by Guggenheim from $80.00 to $65.00 in a report issued on Wednesday morning, Marketbeat reports. They currently have a buy rating on the stock.
Several other equities analysts have also weighed in on the stock. UBS Group assumed coverage on shares of Ionis Pharmaceuticals in a research report on Thursday, October 15th. They set a “buy” rating and a $88.00 price objective for the company. BMO Capital Markets upgraded shares of Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and boosted their target price for the stock from $54.00 to $66.00 in a report on Thursday, October 22nd. Weiss Ratings downgraded shares of Ionis Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday. Canaccord Genuity Group cut their target price on shares of Ionis Pharmaceuticals from $95.00 to $85.00 and set a “buy” rating for the company in a research note on Tuesday, September 8th. Finally, Wells Fargo & Company reduced their target price on shares of Ionis Pharmaceuticals from $95.00 to $80.00 and set an “overweight” rating for the company in a report on Tuesday, November 10th. Nineteen equities research analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $75.00.
Check Out Our Latest Research Report on IONS
Ionis Pharmaceuticals Price Performance
Shares of NASDAQ:IONS opened at $26.58 on Wednesday. The stock has a market cap of $4.43 billion, a price-to-earnings ratio of -8.01 and a beta of 0.43. The company has a debt-to-equity ratio of 3.42, a current ratio of 5.43 and a quick ratio of 5.36. Ionis Pharmaceuticals has a 12 month low of $26.53 and a 12 month high of $86.74. The stock’s 50 day moving average price is $40.76 and its 200 day moving average price is $63.17.
Ionis Pharmaceuticals (NASDAQ:IONS – Get Free Report) last announced its quarterly earnings data on Monday, November 9th. The company reported ($0.66) earnings per share for the quarter, beating the consensus estimate of ($1.23) by $0.57. The business had revenue of $242.72 million during the quarter, compared to analyst estimates of $178.17 million. Ionis Pharmaceuticals had a negative return on equity of 120.62% and a negative net margin of 56.98%. The company’s revenue was up 54.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.80) earnings per share. Equities research analysts anticipate that Ionis Pharmaceuticals will post -3.48 earnings per share for the current fiscal year.
Insider Transactions at Ionis Pharmaceuticals
In other Ionis Pharmaceuticals news, EVP Shannon L. Devers sold 1,357 shares of the company’s stock in a transaction dated Friday, October 16th. The shares were sold at an average price of $43.54, for a total transaction of $59,083.78. Following the completion of the sale, the executive vice president directly owned 17,811 shares of the company’s stock, valued at approximately $775,490.94. This represents a 7.08% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Michael R. Hayden bought 5,000 shares of the firm’s stock in a transaction on Tuesday, November 10th. The stock was purchased at an average price of $29.64 per share, with a total value of $148,200.00. Following the completion of the acquisition, the director owned 27,000 shares of the company’s stock, valued at approximately $800,280. This trade represents a 22.73% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Company insiders own 1.81% of the company’s stock.
Institutional Investors Weigh In On Ionis Pharmaceuticals
Large investors have recently made changes to their positions in the company. Cassaday & Co Wealth Management LLC acquired a new position in shares of Ionis Pharmaceuticals in the first quarter worth $30,000. Allworth Financial LP acquired a new stake in Ionis Pharmaceuticals during the second quarter valued at $41,000. Silvant Capital Management LLC acquired a new stake in Ionis Pharmaceuticals during the second quarter valued at $43,000. Archer Investment Corp acquired a new stake in Ionis Pharmaceuticals during the second quarter valued at $48,000. Finally, Laurel Wealth Advisors LLC acquired a new stake in Ionis Pharmaceuticals during the third quarter valued at $27,000. Institutional investors and hedge funds own 93.86% of the company’s stock.
Key Stories Impacting Ionis Pharmaceuticals
Investors following IONS have been watching these stories:
- Positive Sentiment: HC Wainwright maintained its Buy rating and $70 price target, despite lowering its earnings forecasts. Ionis analyst estimates
- Negative Sentiment: HC Wainwright lowered its earnings estimates across several periods. Its FY2027 loss estimate widened to $1.94 per share from $1.25, and it also cut estimates for Q4 2026 and Q1–Q3 2027. The downward revisions could reinforce concerns about Ionis’s path to profitability. Ionis analyst estimates
- Negative Sentiment: Guggenheim also cut its price target for Ionis, adding to the bearish analyst news; the report provided here does not specify the new target. Ionis Pharmaceuticals stock price target cut by Guggenheim
About Ionis Pharmaceuticals
Ionis Pharmaceuticals is a biotechnology company that discovers and develops RNA-targeted medicines, with a focus on antisense oligonucleotides. Its medicines are designed to act on RNA and change the production of proteins linked to disease. The company’s research and development programs span neurological, cardiovascular, metabolic and rare diseases. Ionis has developed medicines that it commercializes itself and products advanced or marketed with pharmaceutical partners. Its medicines and partnered products include treatments for conditions such as spinal muscular atrophy and transthyretin amyloidosis.
Recommended Stories
- Five stocks we like better than Ionis Pharmaceuticals
- Survey Reveals: How Much Would People Pay for Ribeye Before Giving It Up? [2026]
- If NVIDIA Tightens Its Wallet, These 3 Stocks Could Feel It
- 3 Dividend ETFs Offering Steadier Footing in a Shaky Market
- Lazard’s New ETF Targets Monthly Income With Junk Bonds
Receive News & Ratings for Ionis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ionis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
